Suggestions
Jing Liang
Biotech Entrepreneur and Management Consultant
Jing Liang is the Co-Founder and CEO of Helicore Biopharma, Inc., which was formerly known as Helicore Bioventures I. Based in Barcelona, Spain, he has a background as a biotech entrepreneur and management consultant. Under his leadership, Helicore Biopharma is focused on developing next-generation therapeutics for obesity and has successfully raised $65 million from top venture capitalists to support its clinical-stage initiatives.1
Liang has an extensive career in the biotech sector, having previously founded Heliome Biotech and served as Interim CEO of Micelle BioPharma. He has also held board positions at SIDIS Corp and the Cancer Support Community, showcasing his commitment to both business and community service.23
His educational background includes a Bachelor of Science degree with Honors in Biochemistry from Penn State University and a PhD in Biophysics from The Johns Hopkins University School of Medicine.2
Highlights
I think $AZN should be commended for trying to change clinical practice. Irony is that some doctors will now use other approved SERDs on detected ESR1 mutations.
And I hope oncologists understands the implication of demanding pivotal trials to be crossover/timing design - Implications of cost, # of patients required, time, and ultimately if incentivizes the most innovation and medical progress.
Rooting for Serena-6 to show OS benefit!
I find the ODAC vote on camizestrant a bit depressing. This is what futuristic cancer treatment looks like.
You develop a drug that targets a key resistance mechanism for breast cancer. You develop a non-invasive ctDNA blood test to surveil the emergence of this resistance mutation.
You only give this drug when this mutation was detected, but cancer is still being controlled. "Nip it in the bud" so to speak.
You demonstrate much better PFS than SOC (HR 0.44-0.46). The drug obviously works!
But you have FDA and some ODAC members using the red-herring which are basically:
-
How can you ensure there is a OS benefit after patients moving onto subsequent lines treatments
-
How do you know if you should give this drug early (at detection of resistance mutations) or when it is full blown progression
To answer both of these questions, you need a much larger trials.
If this is the bar for cancer drug approvals, there will be fewer MOAs investigated. The total amount of R&D dollars investors and pharma companies willing to deploy is relatively fixed.
On top of that, there are only so many patients you can recruit. If you demand large trials for a particular MOA, this means fewer patients available for other trials.
The regulatory bar that drives the most human progress is not necessarily the bar that gives you the most certainty.
https://t.co/kRsKurjVdi
